Overview
NMRA market data
Price History
NMRA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.45 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.85 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.83 – $3.65 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $300.2M · P/B 2.88.
Company News
Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) EstimateBenzinga · Aug 14, 2026, 11:18 AM
8-K filing — Neumora Therapeutics, Inc. (NMRA)SEC EDGAR · Aug 14, 2026, 11:13 AM
Why Is BioAge Labs Stock Sinking Friday?Benzinga · Jul 31, 2026, 5:24 PM
Neumora Therapeutics shares are trading lower amid possible sympathy with Novo Nordisk after its ZEUS phase 3 trial did not translate into a MACE risk reduction.Benzinga · Jul 31, 2026, 4:16 PM
CORRECTION: Neumora Therapeutics Reported Pre-Clinical Toxicology Results From NMRA-215 On July 27Benzinga · Jul 31, 2026, 1:41 PM
Neumora Therapeutics shares are trading lower after the company reported pre-clinical toxicology results from NMRA-215. The company conducted a repeat 13-week toxicology study after an audit revealed various discrepancies resulting in several critical audit observations.Benzinga · Jul 31, 2026, 1:40 PM
Neumora Therapeutics Reported Favorable Preclinical Toxicology Results From NMRA-215, An Oral NLRP3 Inhibitor In Development For Obesity And Cardiometabolic Disease; Plans To Submit An IND Application In Q4 Of 2026Benzinga · Jul 27, 2026, 11:03 AM
RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5Benzinga · Jul 13, 2026, 2:09 PM
Datadog, EHang Holdings And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · Jul 6, 2026, 12:05 PM
Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4Benzinga · Jun 18, 2026, 5:45 PM